A detailed history of China Universal Asset Management Co., Ltd. transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 13,354 shares of AKRO stock, worth $391,806. This represents 0.04% of its overall portfolio holdings.

Number of Shares
13,354
Previous 8,124 64.38%
Holding current value
$391,806
Previous $190,000 101.58%
% of portfolio
0.04%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$21.45 - $29.34 $112,183 - $153,448
5,230 Added 64.38%
13,354 $383,000
Q2 2024

Jul 19, 2024

SELL
$18.31 - $24.62 $48,997 - $65,883
-2,676 Reduced 24.78%
8,124 $190,000
Q1 2024

Apr 29, 2024

BUY
$17.76 - $31.18 $77,273 - $135,664
4,351 Added 67.47%
10,800 $273,000
Q4 2023

May 21, 2024

SELL
$11.38 - $50.33 $49,514 - $218,985
-4,351 Reduced 40.29%
6,449 $150,000
Q4 2023

Jan 23, 2024

BUY
$11.38 - $50.33 $57,161 - $252,807
5,023 Added 352.24%
6,449 $151,000
Q3 2023

May 21, 2024

BUY
$41.19 - $52.25 $28,874 - $36,627
701 Added 96.69%
1,426 $72,000
Q3 2023

Oct 30, 2023

BUY
$41.19 - $52.25 $28,874 - $36,627
701 Added 96.69%
1,426 $72,000
Q2 2023

May 21, 2024

BUY
$36.89 - $56.88 $3,356 - $5,176
91 Added 14.35%
725 $33,000
Q2 2023

Jul 27, 2023

BUY
$36.89 - $56.88 $3,356 - $5,176
91 Added 14.35%
725 $34,000
Q1 2023

May 21, 2024

BUY
$37.27 - $50.24 $5,925 - $7,988
159 Added 33.47%
634 $24,000
Q1 2023

Apr 27, 2023

BUY
$37.27 - $50.24 $5,925 - $7,988
159 Added 33.47%
634 $24,000
Q4 2022

May 21, 2024

SELL
$33.44 - $54.8 $345,268 - $565,810
-10,325 Reduced 95.6%
475 $26,000
Q4 2022

Jan 31, 2023

BUY
$33.44 - $54.8 $4,113 - $6,740
123 Added 34.94%
475 $26,000
Q3 2022

Oct 21, 2022

BUY
$10.15 - $34.05 $3,572 - $11,985
352 New
352 $12,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.36B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.